A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma
Previously Treated Amyloid Light-chain (AL) Amyloidosis

Interventions

DRUG: JNJ-79635322

Sponsor

Janssen Research & Development, LLC